Dr. Terrin


Photo of Doctor Michael Terrin

Michael Terrin, M.D.
Professor of Epidemiology & Public Health;
Medicine

Department: Division
Epidemiology & Public Health: Gerontology

Medical Degree: McGill University
MPH: Johns Hopkins University
Fellowship: Pulmonary Medicine, Montreal General Hospital
Pulmonary Medicine, Johns Hopkins Medical Institutions
Certification: Diplomat, American Board of Internal Medicine, Pulmonary Subspecialty

Biography:

  • Adjunct Professor, Dept of Epidemiology and Preventive Medicine (1982-2005)
  • Epidemiologist Maryland Medical Research Institute (1982-present)
  • Vice President Maryland Medical Research Institute (1987-1998)
  • President and Chief Operating Officer Maryland Medical Research Institute (1998-2001)
  • President and Chief Executive Officer Maryland Medical Research Institute (2001-2004)

Research Interest:

Dr. Terrin is one of the nation's foremost clinical trialists who has played a senior role in several large paradigm shifting studies, including:

  • Thrombolysis in Myocardial Infarction (TIMI) Trial, Epidemiologist, Deputy Director, Coordinating Center: Randomized Trial of Two Thrombolytic Agents to Compare Efficacy in Clot Lysis: Management after Thrombolytic Therapy Comparing Routine Performance of Angiography for Revascularization Versus Angiography on Clinical Indication; and, Immediate Intravenous Beta-Blocker Therapy Versus Deferred Beta-Blocker Therapy.

  • Prospective Investigation of Pulmonary Embolism Diagnosis, Principal Investigator, Coordinating Center: Study of V/Q Scanning and Pulmonary Angiography to Establish the Sensitivity and Specificity of V/Q Scans in the Diagnosis of Pulmonary Embolism.

  • Post Coronary Artery Bypass Graft (CABG) Studies, Co-Principal Investigator, Coordinating Center: Randomized Trial with 2 X 2 Factorial Design to Compare Moderate Versus Marked LDL-Cholesterol Reduction and Low Dose Warfarin Versus Placebo in the Prevention of Saphenous Vein Bypass Graft Occlusion; and an Observational Cohort Study of Biobehavioral Status Before and After CABG Surgery.

  • Asymptomatic Cardiac Ischemia Pilot (ACIP) Study, Co-Principal Investigator, Clinical Coordinating Center: Randomized Trial of Three Treatments (Angina-Guided Therapy, Angina-Guided Therapy Plus Ambulatory Electrocardiogram-Guided Therapy and Primary Revascularization) to Determine Their Efficacy in the Reduction of Ambulatory Electrocardiogram (AECG) Documented Ischemia and to Determine the Feasibility of a Larger Study with Clinical End Points.

  • Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH) Principal Investigator, Data Coordinating Center and MSH Patients' Follow-Up, Principal Investigator, Medical Coordinating Center: Randomized, Double-Blind Trial of Hydroxyurea for the Reduction of Acute Vaso-occlusive (Painful) Crises in Patients with Sickle Cell Anemia, and Observational Follow-Up of These Patients to Determine Long-Term Safety.

  • Randomized, Double-blind Controlled Clinical Trial of Ursodeoxycholic Acid in Cystic Fibrosis Associated Liver Disease, Principal Investigator, Coordinating Center: Randomized, Double-Blind Trial of Ursodeoxycholic Acid for the Improvement of Hepatobiliary Function (as Measured by Radionuclide Clearance Half-Time) in Patients with Cystic Fibrosis.

  • Rhode Island Cardiac Services Registry, Project Officer, Data Collection and Data Analysis Contractor (C-TASC): Registry of Angiography, Angioplasty and Cardiac Surgery in the State of Rhode Island.

  • A Case Control Etiologic Study of Sarcoidosis, Co-Principal Investigator, Clinical Coordinating Center: A case control study to determine the etiology of sarcoidosis.

  • A Randomized Study of the Efficacy of Physician Extender-Assisted, Protocolized Care in Heart Failure Outpatients at High Risk for Hospital Readmission (CHF Team Study), Principal Investigator, Data Coordinating Center: Unblinded Trial of a Management Approach to Reduce Hospitalizations for Congestive Heart Failure.

  • Postmenopausal Hormone Therapy in Unstable Angina Study (PMHT), Principal Investigator, Data Coordinating Center: Randomized, Placebo-Controlled, Double-Blind Trial of Estrogen with and without Progesterone to Reduce Ischemia on Holter Monitoring of Post-Menopausal Women with Unstable Angina.

  • A Randomized, Double-Blinded, Placebo-Controlled Trial of the Presumptive Use of Fluconazole in Febrile Intensive-Care Unit Patients at Risk for Fungal Infections, Principal Investigator, Interim Analysis Center: Randomized, Double-Blind Trial of Fluconazole for the Treatment of Febrile Patients in Intensive Care Units.

  • Women and Infants Transmission Study (WITS), Co-Principal Investigator, Statistical and Clinical Coordinating Center: Observational Study of Women Infected with the Human Immunodeficiency Virus (HIV) and Their Children to Establish Risk Factors for HIV Transmission and Determinants of Maternal and Infant Disease Progression, and Infant Growth and Development.

  • Pediatric Hydroxyurea Phase III Clinical Trial, Principal Investigator, Medical Coordinating Center: A randomized, double-blind placebo controlled trial to determine if hydroxyurea can prevent the onset of chronic end organ damage in young children with sickle cell anemia.

  • Occluded Artery Trial, Co-Investigator, Data Coordinating Center: A study to compare the composite outcome of all-cause mortality, non-fatal MI and hospitalization for Class IV CHF based on an average three-year follow-up among patients assigned to two treatment groups (conventional medical management or conventional medical therapy plus percutaneous coronary intervention and coronary stenting).

  • Vascular Interaction with Age in Myocardial Infarction, Principal Investigator, Data Coordinating Center: A randomized placebo controlled clinical trial to test the efficacy of the amino acid L-arginine in the prevention of death or congestive heart failure in elderly patients who have had recent myocardial infarction.

  • Transfusion Therapy Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair, Principal Investigator, Data Coordinating Center: A multi-center randomized trial to test if a more aggressive transfusion strategy that maintains postoperative hemoglobin levels above 10 g/dl improves patient outcome as compared to a more conservative strategy that withholds blood transfusion until the patient develops symptoms of anemia.

  • Current Research Funding:

    R01 (HL-074815) Terrin (PI) 07/10/03-06/30/08
    NHLBI
    FOCUS Data Coordinating Center
    Transfusion Therapy Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)
    A randomized, clinical trial testing which of two blood transfusion regimes (10g/dl trigger or symptomatic trigger) is better for recovery (ability to walk without human assistance) in the management of anemia in elderly, cardiovascular patients who have just had surgical repair for hip fracture.
    Role: PI
     
    N01 (HB-07160) Thompson (PI) 08/01/00-06/30/06
    NHLBI
    Pediatric Hydroxyurea Phase III Clinical Trial
    A randomized, double-blind placebo controlled trial to determine if hydroxyurea can prevent the onset of chronic end organ damage in young children with sickle cell anemia.
    Role: Epidemiologist
     
    Johns Hopkins University School of Medicine Schulman (PI) 09/10/01-08/31/05
       
    (Subcontract)
    Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI)
    A randomized placebo controlled clinical trial to test the efficacy of the amino acid L-arginine in the prevention of death or congestive heart failure in elderly patients who have had recent myocardial infarction.
    Role: Data Coordinating Center PI
       
    N01 (HB-67129) Barton (PI) 12/31/02-12/31/07
    NHLBI
    MSH Patients' Follow Up - Extension I
    The objective of this project is to follow up adult patients who participated in the Multicenter Study of Hydroxyurea in Sickle Cell Disease (MSH) in order to ascertain whether there are any long-term toxic effects of hydroxyurea in this patient population.
    Role: Epidemiologist  
       
    R01 (HL-62511) Knatterud (PI) 09/30/99-08/31/04
    NHLBI
    Occluded Artery Trial (OAT)
    A study to compare the composite outcome of all-cause mortality, non-fatal MI and hospitalization for Class IV CHF based on an average three-year follow-up among patients assigned to two treatment groups (conventional medical management or conventional medical therapy plus percutaneous coronary interventional and coronary stenting).
    Role: Co-PI  
       
    Subcontract from University of Alberta (Dzavik) (PI) 04/01/01-08/31/04
    NHLBI
    TOSCA-2: An Angiographic Substudy of the Occluded Artery Trial
    A study to determine if late PTCA and stenting will result in superior arterial patency that will improve LV function in patients with occluded IRA after a recent MI.
    Role: Data Coordinating Center PI  
       
    Subcontract from University of Maryland (Rashba) (PI) 10/01/02-08/31/04
    NHLBI
    Electrophysiologic Effects of Late PCI (OAT-EP)
    The purpose of this study is to compare opening blocked arteries with balloon angioplasty and stents to medical therapy for effects on heart rate variability and conduction abnormalities.
    Role: Data Coordinating Center PI  
       
    Subcontract from Tufts University/New England Medical Center (Udelson) (PI)  
       
    NHLBI 1/01/04-08/31/04
    Myocardial Viability and Remodeling in the Occluded Artery Trial (OAT-NUC)
    The purpose of this study is to examine: the influence of retained viability within the infarct zone on extent of remodeling in post-MI patients with occluded infarct related arteries (IRAs); the interaction of retained viability of the infarcted segment with extent of remodeling in post-MI patients with occluded IRA randomized to late revascularization versus medical treatment alone; and, the extent of left ventricular remodeling in post-MI patients with occluded IRA randomized to late revascularization versus medical treatment alone.
    Role: Data Coordinating Center PI  

    Education:

    • M.D., C.M. ”“ McGill University (1974)
    • MPH ”“ Johns Hopkins University (1980)
    • House Staff Training: Montreal General Hospital (1975-77)
    • Fellowship Training (if applicable): Pulmonary Medicine, Montreal General Hospital (1977-78) and Johns Hopkins University (1978-80)

    This page was last updated: July 26, 2013

             
    Average rating (1)